2-piperidone has been researched along with Androgen-Independent Prostatic Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; He, M; Kirchhoff, PD; Matvekas, A; McEachern, D; Metwally, H; Miao, B; Qin, C; Sun, D; Wang, L; Wang, S; Wang, Y; Wen, B; Xiang, W; Zhao, L | 1 |
| Chen, S; Cridge, AG; Hawkins, BC; Nimick, M; Rosengren, RJ | 1 |
2 other study(ies) available for 2-piperidone and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Topics: Adaptor Proteins, Signal Transducing; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Male; Mice, SCID; Molecular Structure; Phthalimides; Piperidones; Prostatic Neoplasms, Castration-Resistant; Proteolysis; Receptors, Androgen; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Curcumin; Humans; Male; Piperidones; Prostatic Neoplasms, Castration-Resistant; Pyridines | 2018 |